Medicenna Therapeutics Corp.

OTCPK:MDNA.F Stock Report

Market Cap: US$23.7m

Medicenna Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:MDNA.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 May 26BuyUS$7,244Richard SutinIndividual20,000US$0.36
28 May 26BuyUS$144,874Albert BeraldoIndividual400,000US$0.36
28 May 26BuyUS$7,244Angelos GeorgakisIndividual20,000US$0.36
28 May 26BuyUS$1,811David HymanIndividual50,000US$0.036
28 May 26BuyUS$39,840Fahar MerchantIndividual110,000US$0.36
23 Feb 26BuyUS$2,149Richard SutinIndividual3,000US$0.72
16 Dec 25BuyUS$2,379Albert BeraldoIndividual3,000US$0.79
15 Dec 25BuyUS$68,871Albert BeraldoIndividual85,000US$0.81
15 Dec 25BuyUS$25,800Fahar MerchantIndividual32,000US$0.81
12 Dec 25BuyUS$12,188Fahar MerchantIndividual15,000US$0.81
12 Dec 25BuyUS$8,125David HymanIndividual10,000US$0.81

Insider Trading Volume

Insider Buying: MDNA.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MDNA.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies5,500,0005.96%
Individual Insiders12,413,40513.4%
General Public74,386,79680.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 7 shareholders own 19.41% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.28%
Fahar Merchant
5,793,802US$1.5m-0.8%no data
6.06%
Rosemina Merchant
5,596,490US$1.4m0%no data
5.96%
Aries Biologics Inc
5,500,000US$1.4m0%no data
0.95%
Albert Beraldo
880,113US$225.6k83.3%no data
0.11%
David Hyman
100,000US$25.6k100%no data
0.025%
Richard Sutin
23,000US$5.9k667%no data
0.022%
Angelos Georgakis
20,000US$5.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/04 03:10
End of Day Share Price 2026/08/03 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles ZhuGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.
Dev PrasadLucid Capital Markets